LETTER TO THE EDITOR

COVID-19 vaccine hesitancy among African American hemodialysis patients: A single-center experience

To the Editor,

Presently, much of the American population remains reluctant to the voluntary receipt of the COVID-19 vaccine, despite numerous public health initiatives. Vaccines function as preventive life-saving measures and have been shown to reduce the incidences of disability and death globally. Achieving a high vaccination rate is crucial to successfully reach herd immunity. Notably, about a third of African Americans remain hesitant to receiving the COVID-19 vaccine.² African Americans have also been disproportionately affected by COVID-19 in regard to hospitalizations and death. Scant amounts of literature illustrate the pattern of willingness to receive the COVID-19 vaccine among dialysis patients. This study was done to assess vaccine hesitancy and acceptance among patients at an urban dialysis center, which serves a predominately African American patient population.

Our study consisted of a paper-based survey that was administered to all patients receiving dialysis treatment. Participants were asked whether they were willing to be vaccinated with a COVID-19 vaccine, and if they responded no, further follow-up questions related to contextual, individual/group, and vaccine-specific issues were asked. Additional information collected included whether the patient had received an influenza vaccine this year, whether they knew of someone who had COVID-19, and whether they had discussed COVID-19 vaccine with a healthcare provider. A chi-square analysis was performed on these three responses and possible association with a willingness to receive a COVID vaccine.

A total of 90 patients responded, of which 54 (60%) were male, 75 (83%) identified as African American, and 15 (17%) identified as Hispanic/Latinx. Nearly half of patients (49%) indicated that they would be willing to receive a COVID-19 vaccine, 34% were unwilling to receive the vaccine, and 17% were unsure. Initially, we hypothesized that having a prior personal history of COVID-19 would be associated with accepting the vaccine; however, only the receipt of an influenza vaccine was associated with a willingness to receive the COVID-19 vaccine, p < 0.001. The reduced concerns about the necessity of a COVID-19 vaccine given recent memory of the morbidity and mortality of the disease is concerning. This showed the need for clarification regarding the driving factors behind the hesitancy. Furthermore, the association between receipt of the influenza vaccine and willingness to receive COVID-19 vaccine emphasizes familiar problems. In the United States, influenza vaccine is covered by many health plans, however, patients still denied influenza vaccines due to either misinformation. misconception, or lack of trust³ and this most likely led them to make the same decision when considering a COVID-19 vaccine. This issue is prominent among ethnic minority patients. Danziger reported the facilities with higher proportion of African American patients had significantly lower influenza vaccine acceptance.4 A recent rapid national assessment for COVID-19 vaccination showed the likelihood of participants getting the vaccine was more than 75%. However, there was a large proportion of hesitancy among African Americans and Hispanics.² Our findings showed only half of the respondents agreed to receive the vaccine. This disparity is not new and could be explained based on factors that existed before the COVID-19 pandemic including preexisting vaccine hesitancy, lower access and interaction with healthcare providers, lower participation of minorities in clinical trials, and cost-related concerns.⁵ To address these persistent health disparities, healthcare providers caring for minority patients must collaborate with the partners trusted by the patients to establish trust and identify the best alternatives to enhance the quality of care among the affected population. These findings could help providers to more effectively target messaging around COVID-19 vaccination programs.

As shown in Table 1, a lack of trust and not having adequate information regarding safety and efficacy contribute greatly to the reasons for vaccine hesitancy. Arguably, trust is an intrinsic and potentially modifiable component of successful uptake of a COVID-19 vaccine. Findings from Hovland showed that trust in the authority is strongly associated with vaccine acceptance. 6 Similar to our findings, trusting issues with the authority should be clarified and made a priority to decrease the hesitancy. One study showed an endorsement by Dr. Fauci increased LETTER TO THE EDITOR 411

TABLE 1 Reasons for vaccine hesitancy

| Reasons for vaccine hesitancy | % |
|--|------|
| Contextual influences | |
| I have read many negative reports from social media | 16.3 |
| Religious leader/celebrity/social influencer I trust do not believe in the vaccine | 5.4 |
| I have heard about/witnessed negative historical events concerning vaccines | 14.5 |
| Receipt of vaccine opposes my religious beliefs | 3.6 |
| I do not completely trust of the federal government | 36.4 |
| I do not trust pharmaceutical companies to provide safe and effective vaccine | 23.6 |
| Total | 100 |
| Individual and group influences | |
| Past negative experiences due to vaccine | 1.6 |
| I believe there are better ways to prevent a disease | 11.3 |
| I do not have enough information about this vaccine and its safety | 46.8 |
| Information on side effects has not been openly shared by authorities | 24.2 |
| I do not believe that the vaccine will prevent this disease | 8.1 |
| My family/friends/colleagues are not willing to receive the vaccine | 8.0 |
| Total | 100 |
| Vaccine/vaccination specific influences | |
| I do not believe this vaccine will be safe for me | 26.7 |
| This vaccine has not been tried as rigorously as other vaccines/medications | 26.7 |
| This vaccine may cause pain | 8.9 |
| Receipt of the vaccine is not convenient | 2.2 |
| I do not trust the manufacturer of the vaccine | 28.9 |
| I am afraid the cost may be too great | 2.2 |
| I have had negative experiences with healthcare providers administering vaccines | 4.4 |
| Total | 100 |

uptake and confidence in safety.⁷ This strategy can be utilized by frontline healthcare personals working closely with dialysis patients. As stated by Schaffer, all individuals who interact with patients should be confident about the safety and effectiveness of COVID-19 vaccines.⁸ This is critical for presenting a unified message of strong vaccination support from the medical community.

In conclusion, the uptake rate of COVID-19 vaccine among minority hemodialysis patients was suboptimal. Patient education to combat the misinformation is essential to increase vaccination uptake. To the best of our knowledge, this is the first study that evaluates COVID-

19 vaccine hesitancy among dialysis patients and highlights the need for directed education focusing on the safety and efficacy to promote uptake of the COVID-19 vaccine.

ACKNOWLEDGMENTS

The authors would like to thank all patients for completing the survey. The authors also would like to thank Ms. Lenie Villanueva and all dialysis staff for coordinating the survey.

CONFLICT OF INTEREST

All the authors declare that there is no conflict of interest.

Dhakrit Rungkitwattanakul¹ Dandrew Yabusaki¹
Divita Singh¹
Pamela Lawson²
Uzoamaka Nwaogwugwu³
Oyije Susan Iheagwara³
Constance Mere^{2,3}

¹Department of Clinical and Administrative Pharmacy Sciences, Howard University College of Pharmacy, Washington, D.C, USA ²Howard University Dialysis Center, Washington, D.C, USA ³Division of Nephrology, Department of Medicine, Howard University College of Medicine, Washington, D.C, USA

Correspondence

Dhakrit Rungkitwattanakul, Department of Clinical and Administrative Pharmacy Sciences, Howard University College of Pharmacy, 2400 4th St NW Annex 3, Room 124, Washington, D.C. 22059, USA. Email: dhakrit.rungkitwatt@howard.edu

ORCID

Dhakrit Rungkitwattanakul https://orcid.org/0000-0003-2674-342X

REFERENCES

- Andre FE, Booy R, Bock HL, Clemens J, Datta SK, John TJ, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86(2): 140-6.
- Khubchandani J, Sharma S, Price JH, Wiblishauser MJ, Sharma M, Webb FJ. COVID-19 vaccination hesitancy in the United States: a rapid National Assessment. J Community Health. 2021;46:270–7.
- Quinn SC, Jamison AM, An J, Hancock GR, Freimuth VS. Measuring vaccine hesitancy, confidence, trust and flu vaccine

412 LETTER TO THE EDITOR

uptake: results of a national survey of white and African American adults. Vaccine. 2019;37(9):1168-73.

- Danziger J, Weinhandl E, Friedman D, Mukamal KJ. Racial and ethnic disparities in seasonal influenza vaccination among dialysis facilities in the United States. J Am Soc Nephrol. 2020; 31(9):2117–21.
- Grohskopf LA, Liburd LC, Redfield RR. Addressing influenza vaccination disparities during the COVID-19 pandemic. JAMA. 2020;324(11):1029–30.
- Hovland CI, Weiss W. The influence of source credibility on communication effectiveness. Public Opin Q. 1951;15(4): 635–50.
- 7. Bokemper SE, Huber GA, Gerber AS, James EK, Omer SB. Timing of COVID-19 vaccine approval and endorsement by public figures. Vaccine. 2020;39(5):825–9.
- 8. Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA. 2020;323(24): 2458–9.